** Legend Biotech's LEGN.O shares down 10.4% before the bell on Thurs to $30.03 after $226 mln follow-on priced

** Somerset, New Jersey-headquartered cell therapy firm late Weds sold 7.7 mln American Depositary shares (ADSs) at $29.35

** Offering price is 12.4% discount to stock's last sale on Weds

** Co intends to use net offering proceeds to fund pipeline programs, including LB2501, and for working capital and other general purposes, per the prospectus

** Morgan Stanley, Jefferies, Citigroup and Deutsche Bank joint bookrunners

** On Jun 2, LEGN shares surged 42% to $36.28 after LB2501 showed early promise in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma, a type of blood cancer

** Legend, an affiliate of Hong Kong-listed GenScript Biotech 1548.HK, has about 185.74 mln ADSs outstanding representing about 371.48 mln ordinary shares

** At Weds close, LEGN shares up 54% YTD

** 15 of 17 analysts rate the stock "strong buy" or "buy", 2 "hold"; median PT $60.40, according to LSEG data